The Food and Drug Administration on Tuesday said a Canadian company could sell a generic version of the anticoagulant Plavix, the biggest-selling drug for , the developer of Plavix and the marketing ...

LONDON (Reuters) - Sanofi-Aventis and Bristol-Myers Squibb , which are just recovering from defeating generic competition to their top-selling Plavix drug in the United States, now face a similar ...

ZURICH, Aug 6 (Reuters) - Novartis AG will sell a generic version of Sanofi-Aventis SA's Plavix blood-thinner at a discount of about 25 percent in Germany, it said on Wednesday. Novartis unit Hexal ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

Bristol-Myers Squibb said generic competition on its biggest drug, Plavix, hamstrung third-quarter earnings, while a federal probe expanded to determine whether an ill-fated deal to protect the Plavix ...

NEW YORK — Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version ...

Sanofi-Aventis and Bristol-Myers Squibb have cut a deal with a generic company that could keep a copycat version of their multibillion drug Plavix off the market until 2011. Sanofi-Aventis and Bristol ...

In addition, there were no significant differences between the drug groups in the percent of patients who died or were hospitalized for any reason; had a stroke or transient ischemic attack ; or who ...

Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world’s second-biggest-selling medicine.